title: Immunomodulatory effects of rosuvastatin on hepatic ischemia/reperfusion induced injury.
abstract: Liver ischemia followed by reperfusion results in liver injury which in turn produces and releases destructive proinflammatory cytokines into the circulation causing subsequent damage to other organs. This remains a significant problem for surgical procedures and liver transplantation.
  
  
  OBJECTIVE
  In this study, we show the effect of rosuvastatin on multiple organ dysfunction induced by hepatic/ischemia reperfusion.
  
  
  METHODS
  Hepatic ischemia and reperfusion (I/R) injury was induced in rats, and groups of rats were pretreated with oral rosuvastatin.
  
  
  RESULTS
  Our study detected the levels of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), IL-10, and monocyte chemotactic protein 1 (MCP-1) not only in serum but also in liver, lung, kidney intestine, and heart tissues. Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-α, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production.
  
  
  CONCLUSIONS
  This is the first report of rosuvastatin immunomodulatory effects on multiorgan dysfunction after hepatic I/R. Our data suggest a therapeutic potential for rosuvastatin in attenuating inflammation and modulating immune response independent of lipid lowering effect.
authors.affiliation: Department of Pharmacology & toxicology, Faculty of Pharmacy, Al-Azhar university, Nasr City, Cairo, Egypt.
authors.forename: Azza S
authors.initials: AS
authors.lastname: Awad
authors.forename: Amany
authors.initials: A
authors.lastname: El Sharif
mesh_terms: D000818:Animals; D001769:Blood / Q000187:drug effects / Q000378:metabolism; D018932:Chemokine CCL2 / Q000097:blood / Q000378:metabolism; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D007155:Immunologic Factors / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000097:blood / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism*; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009102:Multiple Organ Failure / Q000097:blood / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000097:blood / Q000150:complications / Q000378:metabolism / Q000517:prevention & control*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000378:metabolism
chemical_list: C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D005464:Fluorobenzenes; D007155:Immunologic Factors; D015850:Interleukin-6; D011743:Pyrimidines; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D000068718:Rosuvastatin Calcium